Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Dose Escalation Study of the Safety, Pharmacokinetics, and Efficacy of the Combination of TMB-365 and TMB-380 in HIV-1 Infected Individuals Suppressed With Combination Antiretroviral Therapy

NCT05275998 is registered in ClinicalTrials.gov with TaiMed Biologics Inc. as lead sponsor.

NCT NCT05275998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05275998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Dose Escalation Study of the Safety, Pharmacokinetics, and Efficacy of the Combination of TMB-365 and TMB-380 in HIV-1 Infected Individuals Suppressed With Combination Antiretroviral Therapy
Lead sponsor
TaiMed Biologics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 5, 2022
Completion date
November 20, 2024
Enrollment
51 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection